Show simple item record

dc.contributor.authorEscribà, Josep M*
dc.contributor.authorPonce, Elisa*
dc.contributor.authorRomero, Alberto de Dios*
dc.contributor.authorViñas, Pedro Albajar*
dc.contributor.authorMarchiol, Andrea*
dc.contributor.authorBassets, Glòria*
dc.contributor.authorPalma, Pedro Pablo*
dc.contributor.authorLima, M Angeles*
dc.contributor.authorZúniga, Concepción*
dc.contributor.authorPonce, Carlos*
dc.date.accessioned2010-11-25T15:58:44Z
dc.date.available2010-11-25T15:58:44Z
dc.date.issued2009-11-01
dc.identifier.citationMem. Inst. Oswaldo Cruz 2009;104(7):986-91en
dc.identifier.issn1678-8060
dc.identifier.pmid20027465
dc.identifier.urihttp://hdl.handle.net/10144/116331
dc.description.abstractBetween 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras. A total of 24,471 children were screened for Trypanosoma cruzi IgG antibodies through conventional enzyme-linked immunosorbent assays (ELISA) on filter paper. Recombinant ELISA (0.93% seroprevalence) showed 256 initially reactive cases, including 232 confirmed positive cases. Of these, 231 individuals were treated with benznidazole (7.5 mg/kg/day) for 60 days and were followed with a strict weekly medical control and follow-up protocol. At the end of the project, 229 patients were examined by the Honduras Secretariat of Health for post-treatment serological assessments; 88.2% seroconverted after 18 months and 93.9% seroconverted after three years. No differences were found in the seroconversion rates according to age or sex. Most of the side effects of the treatment were minor. These results support the argument that in areas where T. cruzi I is predominant and in areas affected by T. cruzi II, when vector transmission has been interrupted, Chagas disease diagnosis and treatment are feasible, necessary and ethically indisputable.
dc.language.isoenen
dc.relation.urlhttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762009000700008&lng=en&nrm=iso&tlng=enen
dc.rightsArchived with thanks to Memórias do Instituto Oswaldo Cruzen
dc.subject.meshAge Distributionen
dc.subject.meshAnimalsen
dc.subject.meshAntibodies, Protozoanen
dc.subject.meshChagas Diseaseen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshChronic Diseaseen
dc.subject.meshEpidemiologic Methodsen
dc.subject.meshFemaleen
dc.subject.meshHondurasen
dc.subject.meshHumansen
dc.subject.meshImmunoglobulin Gen
dc.subject.meshInfanten
dc.subject.meshInsect Controlen
dc.subject.meshMaleen
dc.subject.meshNitroimidazolesen
dc.subject.meshTreatment Outcomeen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosoma cruzien
dc.titleTreatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Hondurasen
dc.typeArticleen
dc.contributor.departmentMédécins Sans Frontières, Barcelona, Spain; Central Reference Laboratory for Chagas Disease and Leishmaniasis; National Chagas Disease Prevention and Control Program, Secretariat of Health, Tegucigalpa, Honduras; Laboratório de Doenças Parasitarias - Medicina Tropical, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasilen
dc.identifier.journalMemórias do Instituto Oswaldo Cruzen
refterms.dateFOA2019-03-04T08:29:58Z
html.description.abstractBetween 1999-2002, Médécins Sans Frontières-Spain implemented a project seeking to determine the efficacy and safety of benznidazole in the treatment of recent chronic Chagas disease in a cohort of seropositive children in the Yoro Department, Honduras. A total of 24,471 children were screened for Trypanosoma cruzi IgG antibodies through conventional enzyme-linked immunosorbent assays (ELISA) on filter paper. Recombinant ELISA (0.93% seroprevalence) showed 256 initially reactive cases, including 232 confirmed positive cases. Of these, 231 individuals were treated with benznidazole (7.5 mg/kg/day) for 60 days and were followed with a strict weekly medical control and follow-up protocol. At the end of the project, 229 patients were examined by the Honduras Secretariat of Health for post-treatment serological assessments; 88.2% seroconverted after 18 months and 93.9% seroconverted after three years. No differences were found in the seroconversion rates according to age or sex. Most of the side effects of the treatment were minor. These results support the argument that in areas where T. cruzi I is predominant and in areas affected by T. cruzi II, when vector transmission has been interrupted, Chagas disease diagnosis and treatment are feasible, necessary and ethically indisputable.


Files in this item

Thumbnail
Name:
091101_Escriba_Chagas-rx-Hondu ...
Size:
509.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record